Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Oudard, S. M.; Bevans, K. B.; Attard, G.; Efstathiou, E.; Flaig, T. W.; Franke, F. A.; Goodman, O. B. Jr; De Giorgi, U.; Pieczonka, C. M.; Yeruva, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
    Meeting Abstract

    Smith, M. R.; Sandhu, S. K.; George, D. J.; Chi, K. N.; Saad, F.; Thiery-Vuillemin, A.; Stahl, O.; Olmos, D.; Danila, D.; Gafanov, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
    Meeting Abstract

    Drilon, A.; Shen, L.; van Tilburg, C. M.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; Doz, F.; McDermott, R.; Albert, C. M.; Berlin, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Brose, M. S.; Shen, L.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; McDermott, R.; Berlin, J.; Tahara, M.; Lassen, U. N.; Leyvraz, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
    Meeting Abstract

    Laetsch, T. W.; van Tilburg, C. M.; Kummar, S.; Dowlati, A.; Guiver, K.; Fellous, M.; Brega, N.; De La Cuesta, E.; Shurshalina, A.; Drilon, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) for previously treated, microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Meeting Abstract

    Le, D. T.; Diaz, L.; Kim, T. W.; Van Cutsem, E.; Geva, R.; Jäger, D.; Hara, H.; Burge, M.; O'Neil, B.; Kavan, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
    Meeting Abstract

    Fakih, M.; Falchook, G. S.; Hong, D. S.; Yaeger, R. D.; Chan, E.; Mather, O.; Cardona, P.; Dai, T.; Strickler, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE
    Meeting Abstract

    Sanz Garcia, E.; Riely, G. J.; Lepisto, E. M.; LeNoue-Newton, M. L.; Warner, J. L.; Sweeney, S. M.; McCarthy, C. G.; Weiss, J.; Yu, C.; Voon, P. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in patients with locally advanced/ metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Meeting Abstract

    Bazhenova, L.; Liu, S. V.; Lin, J. J.; Lu, S.; Drilon, A.; Chawla, S. P.; Fakih, M.; Krzakowski, M.; Paz-Ares, L.; Blakely, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save